Antimalarial drug toxicity: a review.

Area of Science:

• Tropical Medicine
• Infectious Diseases
• Pharmacology

Background:

• Malaria, primarily caused by Plasmodium falciparum and P. vivax, is a major global health concern.
• Antimalarial drug toxicity presents a complex risk-benefit challenge, particularly for vulnerable populations such as young children and pregnant women.
• Limited antimalarial drug options and unclear risk-benefit ratios complicate prescribing, especially during pregnancy.

Purpose of the Study:

• To review the safety and efficacy profiles of various antimalarial drugs.
• To highlight the challenges in antimalarial drug use, particularly concerning toxicity and vulnerable populations.
• To discuss the potential of artemisinin derivatives and combination therapies in malaria control.

Main Methods:

• Literature review of existing antimalarial drugs and their adverse effects.
• Analysis of drug tolerability and efficacy for treatment and prophylaxis.
• Examination of specific challenges related to prescribing antimalarials in pregnancy and for children.
• Evaluation of newer antimalarial agents and combination strategies.

Main Results:

• Chloroquine remains a first-choice treatment for P. vivax malaria despite decreasing efficacy against P. falciparum, with pruritus as a common side effect.
• Sulfadoxine/pyrimethamine is well-tolerated for treatment and intermittent preventive therapy in pregnant women but is no longer used for prophylaxis due to severe adverse event risks.
• Mefloquine is valuable for prophylaxis and treatment, though neuropsychiatric toxicity can occur; it's contraindicated in patients with epilepsy or psychiatric conditions.
• Artemisinin derivatives demonstrate remarkable efficacy and an excellent safety record with no identifiable dose-related adverse effects, making them a key class for malaria control.
• Atovaquone/proguanil shows good efficacy and tolerability for both prophylaxis and treatment.
• Combination therapy, particularly with artemisinin derivatives, is increasingly recognized as the optimal strategy for malaria treatment.

Conclusions:

• Antimalarial drug selection requires careful consideration of the risk-benefit profile, especially in vulnerable populations.
• Artemisinin-based combination therapies represent a significant advancement in malaria treatment due to their high efficacy and safety.
• Further research and development are needed to address the challenges of antimalarial drug toxicity and expand treatment options, particularly for specific patient groups.